Africa

Congi Ebola vaccine trials offer fresh hope

Two new vaccines made for a deadly type of Ebola called Bundibugyo will soon be tested on people in eastern Democratic Republic of Congo. The World Health Organization (WHO) says testing could start as early as next week. The news comes as the country faces the worst Ebola outbreak in its history, and it gives families and health workers a reason for careful hope.

What WHO announced

Speaking to reporters in Geneva on Tuesday, WHO chief Tedros Adhanom Ghebreyesus said two vaccines designed specifically for the Bundibugyo virus are expected to begin testing very soon. Meg Doherty, who heads WHO's science department, said the next stage of testing is planned for 26 or 27 November in Bunia, the main city of Ituri province, where the outbreak is at its worst.

One vaccine comes from the University of Oxford. The other was made by the American company Moderna, using the same kind of technology that became well known during the Covid-19 pandemic. Both have already passed a first round of small safety checks.

They will join a study called Tumaini, which began on 23 October. That study is testing a vaccine called Ervebo, which is approved for the more common type of Ebola, to see whether it also gives some protection against Bundibugyo. More than 140 people have joined so far, and thousands more are expected to sign up. The study will also spread beyond Bunia to other places.

Why the trials matter now

The need is urgent. WHO says 11,376 people have been confirmed with Ebola and 5,568 have died. It is the worst outbreak Congo has ever faced and the second-largest in the world on record. Between 400 and 500 new cases are still being found every week.

Right now there is no vaccine and no treatment made for Bundibugyo. A shortage of resources, unrest in the region and poor coordination have made the fight harder.

Children are among the hardest hit. Tedros said they make up more than a quarter of cases and a third of deaths. He also said two out of every three deaths are still happening outside treatment centres.

The study offers vaccine to people who have been close to someone with Ebola, because they are the most likely to catch it next.

What 'trial' means, and what 'approved use' means

A trial is a research study. Its job is to find out whether a vaccine is safe and whether it helps the body fight the virus. If the early results look good, the vaccines can move to a much bigger study that checks whether they really protect people.

'Approved use' comes much later. It means experts have checked all the evidence and decided the vaccine is safe and works well enough to be given widely. The two Bundibugyo vaccines are not at that point. They are still experimental, and only people who join the study receive them.

So the trials are a promising step, not a cure and not a promise. Until a proven vaccine is ready, the simple steps still save lives: get medical help early, tell health workers about anyone who may be sick, and follow their advice on keeping sick people apart and on safe burials.

Sources

  1. World Health Organization (WHO). Official website and news updates on Ebola. https://[www.who.int]
  2. World Health Organization (WHO). Dr Tedros Adhanom Ghebreyesus, Director-General. https://[www.who.int/director-general/tedros-adhanom-ghebreyesus]
  3. RFI (with AFP). "Strain-specific Ebola vaccines to be trialled in DRC, WHO announces", 18 November 2026. https://[www.rfi.fr/en/africa/20261118-strain-specific-ebola-vaccines-to-be-trialled-in-drc-who-announces]
  4. Reuters. Ebola outbreak coverage. https://[www.reuters.com]

Version 1.0. 54gist stories are edited before publication and updated as facts change. Spotted an error? Tell our editors.